Inhibrx, Inc (INBX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Mark P. Lappe |
| Employees: | 110 |
| Web site: | inhibrx.com |
|
11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA, CA, 92037
(858) 795-4220
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Are you looking for this stock instead?
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma.
Please log in first to see chart